Xilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% – What’s Next? - American Market News
Author: ABMN Staff
Description: Read Xilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% – What’s Next? at American Market News
Keywords: Xilio Therapeutics,NASDAQ:XLO,XLO,Medical,Stocks,Technicals
Date: 2026-06-09T01:14:49+0000

Skip to main content

# Xilio Therapeutics (NASDAQ:XLO) Shares Down 0.3% – What’s Next?

Posted by ABMN Staff on Jun 9th, 2026

Share on Twitter
Share on Facebook
Share on LinkedIn
Share on Stocktwits

Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report)’s stock price fell 0.3% during trading on Monday . The company traded as low as $7.60 and last traded at $7.68. 22,149 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 61,076 shares. The stock had previously closed at $7.70.

Get Xilio Therapeutics alerts:

## Analysts Set New Price Targets

A number of brokerages recently commented on XLO. Wall Street Zen downgraded shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Check Out Our Latest Report on Xilio Therapeutics

## Xilio Therapeutics Price Performance

The company’s fifty day simple moving average is $8.26 and its 200-day simple moving average is $8.62. The firm has a market capitalization of $50.53 million, a PE ratio of -2.16 and a beta of -0.12.

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.08. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%. The business had revenue of $12.65 million for the quarter, compared to analyst estimates of $8.52 million.

## Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of XLO. Squarepoint Ops LLC grew its holdings in Xilio Therapeutics by 39.6% in the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares during the last quarter. Empery Asset Management LP purchased a new position in Xilio Therapeutics in the fourth quarter worth $757,000. Renaissance Technologies LLC grew its holdings in Xilio Therapeutics by 68.3% in the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after purchasing an additional 139,716 shares during the last quarter. Jane Street Group LLC purchased a new position in Xilio Therapeutics in the fourth quarter worth $27,000. Finally, State Street Corp grew its holdings in Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares during the last quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

## About Xilio Therapeutics

(Get Free Report)

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.

## Further Reading

- Five stocks we like better than Xilio Therapeutics
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

## You might be interested in:

ProShares Ultra Nasdaq Cloud Computing ETF Shares Down 1.5% – What’s Next?
Wheels Up Experience Trading 0.2% Higher – Time to Buy?
Branicks Group Shares Down 7.3% – Here’s What Happened
Cizzle Biotechnology Trading Down 6.4% – Here’s What Happened
SmartETFs Dividend Builder ETF Shares Down 0.1% – Here’s What Happened
Jasper Therapeutics Trading Down 5% – Should You Sell?